Literature DB >> 7719914

Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays.

L Bélec1, D Meillet, M Lévy, A Georges, C Tévi-Bénissan, J Pillot.   

Abstract

Local immunological defense mechanisms in the cervicovaginal mucosa currently remain incompletely defined, especially from a quantitative point of view. Addition of an inert substance, lithium chloride (LiCl), into the washing buffer used to carry out the vaginal washing for collecting cervicovaginal secretions and measurement of its concentration with a flame absorption spectrophotometer, before and after the specimen is sampled, permits the quantification of the volume of cervicovaginal secretions collected and the approximation of the dilution factor of a soluble component introduced by the washing. Lithium, at a concentration of 10 mM, gives the best precision of measurement and has no effect on the results of the immunoassays. In a population of 27 nonpregnant women (age range, 18 to 45 years), the volume of cervicovaginal secretions collected by vaginal washing with 3 ml of LiCl-phosphate-buffered saline was 12% +/- 3.2% (mean +/- standard deviation) of the total volume and showed large interindividual variations (range, 5.6 to 18.8%); the mean dilution factor of a soluble component from the vaginal secretions was 9.9% +/- 2.8% (range, 6.3 to 18.8%). According to the date of the menstrual cycle, the mean volume of collected cervicovaginal secretions was significantly increased in the luteal phase in comparison with the follicular phase; conversely, the mean dilution factor of a soluble component was more important in the follicular than in the luteal phase. These features strengthen the need to quantify accurately the dilution factor introduced by vaginal washing when studying cervicovaginal immunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719914      PMCID: PMC170101          DOI: 10.1128/cdli.2.1.57-61.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  5 in total

1.  Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein.

Authors:  T Lehner; L A Bergmeier; C Panagiotidi; L Tao; R Brookes; L S Klavinskis; P Walker; J Walker; R G Ward; L Hussain
Journal:  Science       Date:  1992-11-20       Impact factor: 47.728

2.  Immunoglobulin G antibody capture enzyme-linked immunosorbent assay: a versatile assay for detection of anti-human immunodeficiency virus type 1 and 2 antibodies in body fluids.

Authors:  P Thongcharoen; C Wasi; S Louisirirotchanakul; J Parry; J Connell; P Mortimer
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

3.  Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women.

Authors:  L Belec; A J Georges; G Steenman; P M Martin
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

4.  Anti-gp160 IgG and IgA antibodies associated with a large increase in total IgG in cervicovaginal secretions from human immunodeficiency virus type 1-infected women.

Authors:  X S Lu; L Bélec; J Pillot
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

5.  New method to assess dilution of secretions for immunological and microbiological assays.

Authors:  A Virolainen; M J Mäkelä; E Esko; J Jero; G Alfthan; J Sundvall; M Leinonen
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

  5 in total
  40 in total

1.  Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women.

Authors:  Caroline Mitchell; Kathleen Paul; Kathy Agnew; Reggie Gaussman; Robert W Coombs; Jane Hitti
Journal:  J Clin Microbiol       Date:  2010-11-24       Impact factor: 5.948

2.  Dilution assessment of cervicovaginal secretions collected by vaginal washing to evaluate mucosal shedding of free human immunodeficiency virus.

Authors:  A S Mohamed; P Becquart; H Hocini; P Métais; M Kazatchkine; L Bélec
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

3.  Comparison of cervicovaginal humoral immunity in clinically asymptomatic (CDC A1 and A2 category) patients with HIV-1 and HIV-2 infection.

Authors:  L Bélec; C Tévi-Bénissan; T Dupré; A S Mohamed; T Prazuck; J Gilquin; J M Kanga; J Pillot
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

4.  Activity of Genital Tract Secretions and Synthetic Antimicrobial Peptides against Group B Streptococcus.

Authors:  Nidhi Agarwal; Niall Buckley; Natasha Nakra; Philip Gialanella; Weirong Yuan; Jeny P Ghartey
Journal:  Am J Reprod Immunol       Date:  2015-09-23       Impact factor: 3.886

5.  In vivo semen-associated pH neutralization of cervicovaginal secretions.

Authors:  C Tevi-Bénissan; L Bélec; M Lévy; V Schneider-Fauveau; A Si Mohamed; M C Hallouin; M Matta; G Grésenguet
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

6.  Changes in the soluble mucosal immune environment during genital herpes outbreaks.

Authors:  Marla J Keller; Rebecca P Madan; Gail Shust; Colleen A Carpenter; N Merna Torres; Sylvia Cho; Hnin Khine; Meei-Li Huang; Lawrence Corey; Mimi Kim; Betsy C Herold
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

7.  Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Authors:  Francois-Xavier Mbopi-Kéou; Laurent Bélec; Julie Dalessio; Jérôme Legoff; Gérard Grésenguet; Philippe Mayaud; David W G Brown; Rhoda Ashley Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

8.  Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samples.

Authors:  Scott A Churchman; John A Moss; Marc M Baum
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-03-02       Impact factor: 3.205

9.  Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions.

Authors:  Jobin Eslahpazir; Mohammad-Ali Jenabian; Hicham Bouhlal; Hakim Hocini; Cédric Carbonneil; Gérard Grésenguet; François-Xavier Mbopi Kéou; Jérôme LeGoff; Héla Saïdi; Mary Requena; Nadine Nasreddine; Jean de Dieu Longo; Srinivas V Kaveri; Laurent Bélec
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

10.  Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.

Authors:  John A Moss; Irina Butkyavichene; Scott A Churchman; Manjula Gunawardana; Rob Fanter; Christine S Miller; Flora Yang; Jeremiah T Easley; Mark A Marzinke; Craig W Hendrix; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.